Alma Bio Therapeutics pioneers a completely novel type of treatment for Autoimmune Diseases.

Its  therapeutic rationale is derived from the understanding of the underlying causes of autoimmune disease and the physiologic mechanisms that manage and regulate inflammation. Thus, it is safe and curative and suitable for large and diverse patient populations.

By employing the body’s own immune regulator molecules as a treatment to regulate the immune system,  Alma therapy reinstates strict control over the aberrant inflammatory reaction without compromising the essential beneficial immune response.

Alma addresses complex autoimmune diseases arising from dysbiosis;   its initial clinical indication is Inflammatory Bowel Disease (IBD), a debilitating disease affecting the quality of life of young adults; other preclinical projects will be established jointly with French and international partners.

Alma is commercializing the discoveries of the Professor Irun Cohen of the Weizmann Institute, AESKU and Robert Koch Prize Laureate.